Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.



Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.

Contact SupportLog In

$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Topics Jun 21 | 2025ADA 2025 Key Press Releases (June 20) Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 16 | 2025Obesity Spotlight: Regeneron’s Obesity Strategy Continues to EvolvePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jun 12 | 2025Novo Advances Amycretin to Ph3; Medtronic Diabetes Reclaims MiniMed Name; Vertex Layoffs After Failed T1DM Program Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Jun 02 | 2025Obesity Spotlight: If Pfizer Can't Beat 'Em, Should It Join Them?Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other, Topics May 21 | 2025Medtronic to Spin Off Diabetes Business and CY Q1 '25 (FY Q4 '25) Earnings; Akero Acquisition Rumor Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Insulin Delivery, Other, Topics May 20 | 2025Noom Offers Lower-Dose Wegovy; Tandem’s Mobi Receives CE Mark; Ascletis Ph1 Obesity Study Purchase Blast
1 2 3 102